接受铂类/紫杉烷方案作为一线化疗的复发性卵巢癌女性患者三线化疗的疗效
Effects of third-line chemotherapy for women with recurrent ovarian cancer who received platinum/taxane regimens as first-line chemotherapy.
作者信息
Chiyoda T, Tsuda H, Nomura H, Kataoka F, Tominaga E, Suzuki A, Susumu N, Aoki D
机构信息
Department of Obstetrics and Gynecology, School of Medicine, Keio University, Tokyo, Japan.
出版信息
Eur J Gynaecol Oncol. 2010;31(4):364-8.
PURPOSE
At present, it remains unclear whether the third-line chemotherapy has clinical benefit. In this study, we retrospectively evaluated the effect of third-line chemotherapy.
METHODS
We reviewed the medical records of 40 women with recurrent epithelial ovarian cancer (EOC) who received third-line chemotherapy after platinum/taxan regimens as first line chemotherapy.
RESULTS
In the first recurrence, 23 cases were platinum-sensitive and 17 cases were platinum-resistant. The cases for which the treatment-free interval from second-line chemotherapy (TFI) was a 3 months had a higher non-PD rate than those with TFI < 3 months (86% vs 33%, p = 0.002). In addition, the median overall survival (OS) was longer for TFI > or = 3 months than for TFI < 3 months (1195 days vs 235 days, p = 0.004). Finally, TFI was an independent significant prognostic factor by univariate (HR 3.28, p = 0.006) and multivariate (HR 3.21, p = 0.018) proportional hazard tests.
CONCLUSION
TFI from second-line chemotherapy may predict a survival benefit of third-line chemotherapy.
目的
目前，三线化疗是否具有临床获益尚不清楚。在本研究中，我们回顾性评估了三线化疗的效果。
方法
我们回顾了40例复发性上皮性卵巢癌（EOC）患者的病历，这些患者在接受铂类/紫杉烷方案作为一线化疗后接受了三线化疗。
结果
在首次复发时，23例对铂敏感，17例对铂耐药。二线化疗后无治疗间期（TFI）≥3个月的患者非疾病进展（non-PD）率高于TFI<3个月的患者（86%对33%，p = 0.002）。此外，TFI≥3个月的患者中位总生存期（OS）长于TFI<3个月的患者（1195天对235天，p = 0.004）。最后，通过单因素（HR 3.28，p = 0.006）和多因素（HR 3.21，p = 0.018）比例风险试验，TFI是一个独立的显著预后因素。
结论
二线化疗后的TFI可能预测三线化疗的生存获益。
Zotero 插件